Guess the next CR date competition, page-26

I’m saying no to CR provided they negotiate an upfront payment in the next 12 months. Reason below

Id like to see a partnership with Astex based off first readouts in the EMD trial.

Given the rare indication, Approval pathway, and unmet clinical need it won’t require the normal amount of funding to market. Astex could be in market within a couple of years without a lot of R&D spend.

I think it makes sense for RAC to licence it in EMD, give the reigns to Astex in the form of an up front payment of say $50-100m (or a lot more) and retain 15% royalties for example.
That upfront can be the used to progress 5-8 other indications where they then rinse and repeat licensing out with upfront/retained royalties.

if RAC went private & spun out publicly listed companies/per licence, they could progress new indications, shareholders collect royalties for the next decade + , and No major buyout, unless BP swallows the spun off company which could be worth 10- 20x the revenue it’s generating. (PE ratio on a revenue generating company is much higher than a 3-5x premium on a development company)


Anyone with more than 10,000 shares would have more income and money than they know what to do with for the next 15-20 years